Open AccessThe development of HEC-866 and its analogues for the treatment of idiopathic pulmonary fibrosis
Author(s) -
Runfeng Lin,
Zheng Zhang,
Shengtian Cao,
Wen Chun Yang,
Yinglin Zuo,
Xinye Yang,
Jiancun Zhang,
Juan Xu,
Jing Li,
Xiaojun Wang
Publication year - 2021
Publication title -
rsc medicinal chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.754
H-Index - 55
ISSN - 2632-8682
DOI - 10.1039/d1md00023c
Subject(s) - pirfenidone , idiopathic pulmonary fibrosis , medicine , pulmonary fibrosis , intensive care medicine , fibrosis , lung
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a typical survival time between three to five years. Two drugs, pirfenidone and nintedanib have been approved for the treatment of IPF, but they have limited efficacy. Thus, the development of new drugs to treat IPF is an urgent medical need. In this paper we report the discovery of a series of orally active pyrimidin-4(3 H )-one analogs which exhibit potent activity in in vitro assays. Among them, HEC-866 showed promising efficacy in rat IPF models. Since HEC-866 also had good oral bioavailability, a long half-life and favorable long-term safety profiles, it was selected for further clinical evaluation.